Skip to main content
    N

    NanoViricides Inc (NNVC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.24
    +0.00 (+0.41%)

    Market Cap: $31.41M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    NanoViricides Inc (NNVC) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    NanoViricides reported revenue of $0 for the fiscal year ended Jun 30, 2026. That year, net income was -$8.22M, operating cash flow was -$7.70M and free cash flow was -$7.78M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$5.74M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Jun 2026, with an operating loss of $8.31M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Jun 2026$0N/AN/AN/AN/A
    Jun 2025$0N/AN/AN/AN/A
    Jun 2024$0N/AN/AN/AN/A
    Jun 2023$0N/AN/AN/AN/A
    Jun 2022$0N/AN/AN/AN/A
    Jun 2021$0N/AN/AN/AN/A
    Jun 2020$0N/AN/AN/AN/A
    Jun 2019$0N/AN/AN/AN/A
    Jun 2018$0N/AN/AN/AN/A
    Jun 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Jun 2017 to Jun 2026

    Income Statement

    In the fiscal year ended Jun 2026, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Research and development$4.71M$5.55M$5.44M$6.39M$5.78M$6.11M$4.70M$5.92M$5.91M$6.57M
    Operating income-$8.31M-$9.59M-$8.52M-$8.94M-$8.11M-$8.74M-$15.99M-$8.66M-$9.33M-$9.60M
    Net income-$8.22M-$9.47M-$8.29M-$8.59M-$8.11M-$8.82M-$13.45M-$8.42M-$8.56M-$10.30M
    EBITDA-$7.69M-$8.72M-$7.49M-$7.84M-$7.38M-$8.01MN/A-$7.73M-$5.99M-$7.18M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Gross profit$0N/A$0$0$0-$161.13K$0$0$0-$190.60K$0$0
    Operating income-$5.77M-$2.25M-$2.03M-$2.23M-$1.80M-$2.12M-$2.25M-$2.06M-$3.17M-$2.39M-$1.91M-$2.18M
    Net income-$5.74M-$2.22M-$1.99M-$2.22M-$1.79M-$2.10M-$2.22M-$2.03M-$3.13M-$2.36M-$1.85M-$2.11M
    Last 12 quarters

    Balance Sheet

    As of Jun 2026, cash and equivalents of $2.79M were 28.3% of total assets of $9.87M, against total liabilities of $1.19M.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Total assets$9.87M$8.82M$12.82M$16.90M$23.49M$30.26M$23.91M$13.45M$18.55M$27.00M
    Current assets$3.16M$1.67M$4.97M$8.45M$14.42M$20.82M$13.99M$2.83M$7.32M$15.29M
    Cash and equivalents$2.79M$1.56M$4.80M$8.15M$14.07M$20.52M$13.71M$2.56M$7.08M$15.10M
    Total liabilities$1.19M$1.31M$1.36M$2.03M$412.84K$351.15K$2.16M$2.85M$881.95K$6.68M
    Short-term debtN/AN/AN/AN/A$94.79K$95.31K$1.14M$1.65MN/A$3.96M
    Shareholder equity$8.68M$7.52M$11.46M$14.87M$23.08M$29.91M$21.76M$10.60M$17.66M$20.32M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$9.56M$9.87M$10.22M$12.27M$8.36M$8.82M$10.03M$11.57M$11.74M$12.82M$11.46M$13.40M
    Total liabilities$3.15M$1.19M$1.07M$1.20M$1.18M$1.31M$1.20M$1.18M$1.63M$1.36M$813.34K$951.07K
    Cash and equivalents$2.58M$2.79M$3.21M$5.15M$1.13M$1.56M$2.54M$3.96M$3.87M$4.80M$3.26M$5.25M
    Shareholder equity$6.41M$8.68M$9.15M$11.07M$7.17M$7.52M$8.83M$10.39M$10.11M$11.46M$10.65M$12.45M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Jun 2026.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Operating cash flow-$7.70M-$8.48M-$6.32M-$5.67M-$5.89M-$8.21M-$6.67M-$6.80M-$7.78M-$7.90M
    Capital expenditures$84.32K$56.96K$156.56K$151.71K$324.35K$238.76K$8.64K$73.79K$241.82K$164.98K
    Free cash flow-$7.78M-$8.54M-$6.47M-$5.82M-$6.22M-$8.45M-$6.67M-$6.88M-$8.02M-$8.06M
    Investing cash flow-$84.32K-$56.96K-$156.56K-$151.71K-$324.35K-$238.76K-$8.64K-$73.79K-$241.82K$0
    Financing cash flow$9.02M$5.30M$3.12M-$94.79K-$234.72K$15.26M$17.83M$2.35M$0$0
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.64M-$2.12M-$1.93M-$2.05M-$1.59M-$1.70M-$1.99M-$2.19M-$2.59M-$1.48M-$1.94M-$1.72M
    Capital expenditures$0$1$2$1$84.32K$10.20K$5$5$46.76K$98.16K$44.63K$5.47K
    Free cash flow-$3.64M-$2.12M-$1.93M-$2.05M-$1.68M-$1.71M-$1.99M-$2.19M-$2.64M-$1.58M-$1.99M-$1.72M
    Last 12 quarters

    Frequently Asked Questions About NNVC

    What is NanoViricides' annual revenue?

    NanoViricides reported revenue of $0 for the fiscal year ended Jun 30, 2026.

    Is NanoViricides profitable?

    No. NanoViricides reported net income of -$8.22M for the fiscal year ended Jun 30, 2026.

    How much free cash flow does NNVC generate?

    For the fiscal year ended Jun 30, 2026, operating cash flow of -$7.70M minus capital expenditures of $84.32K produced free cash flow of -$7.78M.

    How much debt does NanoViricides have?

    The balance sheet dated Jun 30, 2026 reported cash and equivalents of $2.79M.